Remus Pharmaceuticals Limited IPO (Remus Pharmaceuticals IPO) Detail

 

Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distributing of finished formulations of pharmaceutical drugs.

The product offerings of the company can be classified into two major categories:

• APIs: Active Pharmaceutical Ingredient (API) is the biologically active component of a drug product (tablet, capsule, cream, injectable) that produces the intended effects.

• Finished Pharmaceutical Formulations: Finished pharmaceutical formulations are therapeutic drugs available in different dosage forms.

The product portfolio consists of 429 products, as on January 31, 2023. They operate under different brand names across the globe. As on January 31, 2023, the company has 295 products registered in a total of 13 countries. As on January 31, 2023, a total of 134 ;products are under the process of registration in 16 countries.

As on January 31, 2023, Remus Pharmaceuticals had business-to-business supply agreements with 58 domestic distributors and 139 international distributors for distribution and/or contract manufacturing supply.

The company has cultivated strong and dependable customer relationships and its clients are spread in more than 20 countries. These clients range from Generic distributors, regional distributors, and Multinational distributors to Hospitals and Clinics.

Remus Pharmaceuticals IPO Details

Remus Pharmaceuticals IPO is a Book Built Issue. The IPO total issue size is Rs 47.69 Cr. The Remus Pharmaceuticals IPO price is ₹1150 to ₹1229 per share. The IPO will list on NSE SME.

IPO Date	May 17, 2023 to May 19, 2023
Listing Date	May 29, 2023
Face Value	₹10 per share
Price	₹1150 to ₹1229 per share
Lot Size	100 Shares
Total Issue Size	388,000 shares (aggregating up to ₹47.69 Cr)
Fresh Issue	388,000 shares (aggregating up to ₹47.69 Cr)
Issue Type	Book Built Issue IPO
Listing At	NSE SME
Share holding pre issue	1,085,000
Share holding post issue	1,473,000
Market Maker portion	19,500 shares

Remus Pharmaceuticals IPO Reservation

Remus Pharmaceuticals IPO a total of 407,500 shares are offered. QIB: 138,750 (34.05%), RII: 97,125 (23.83%), NII: 41,625 (10.21%).

Anchor Investor Shares Offered	110,500 (27.12%)
Market Maker Shares Offered	19,500 (4.79%)
QIB Shares Offered	138,750 (34.05%)
NII (HNI) Shares Offered	41,625 (10.21%)
Retail Shares Offered	97,125 (23.83%)
Total Shares Offered	407,500 (100%)

Remus Pharmaceuticals IPO Timetable (Tentative)

Remus Pharmaceuticals IPO opens on May 17, 2023, and closes on May 19, 2023.

IPO Open Date	Wednesday, 17 May 2023
IPO Close Date	Friday, 19 May 2023
Basis of Allotment	Wednesday, 24 May 2023
Initiation of Refunds	Thursday, 25 May 2023
Credit of Shares to Demat	Friday, 26 May 2023
Listing Date	Monday, 29 May 2023
Cut-off time for UPI mandate confirmation	5 PM on May 19, 2023

Remus Pharmaceuticals IPO Lot Size

The minimum lot size of this Remus Pharmaceuticals IPO is 100 shares required is ₹122,900.

Application	Lots	Shares	Amount
Retail (Min)	1	100	₹122,900
Retail (Max)	1	100	₹122,900
HNI (Min)	2	200	₹245,800

Remus Pharmaceuticals IPO Promoter Holding

Mr. Arpit Deepakkumar Shah, Ms. Roma Vinodbhai Shah, Mr. Swapnil Jatinbhai Shah, and Mrs. Anar Swapnil Shah are the Promoters of the company.

Pre Issue Share Holding	92.82%
Post Issue Share Holding	68.37%

Company Financials

Period Ended	Total Assets	Total Revenue	Profit After Tax	Net Worth	Reserves and Surplus	Total Borrowing
31-Mar-20	530.36	1,276.89	81.16	202.03	201.03	35.93
31-Mar-21	1,104.96	1,922.45	102.58	304.61	303.61	27.89
31-Mar-22	1,590.93	2,543.71	338.57	643.17	543.17	19.17
31-Dec-22	3,352.96	3,361.20	643.90	1,712.07	1,603.57	947.45
Amount in ₹ Lakhs

Key Performance Indicator

Remus Pharmaceuticals IPO Market Cap is Rs 181.03 Cr and P/E (x) is 21.09.

KPI	Values
P/E (x)	21.09
Market Cap (₹ Cr.)	181.03
ROE	71.44%
ROCE	69.99%
Debt/Equity	0.03
EPS (Rs)	33.86
RoNW	52.64%